Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-05-19

Last Posted Date: 2016-06-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 584

Registration Number: NCT00003117

Locations: 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 32 locations

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-05-17

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 30

Registration Number: NCT00083057

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Metabolism Branch;MET, Bethesda, Maryland, United States

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2004-05-17

Last Posted Date: 2011-03-01

Lead Sponsor: American College of Radiology Imaging Network

Target Recruit Count: 250

Registration Number: NCT00083083

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States

and more 46 locations

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-05-12

Last Posted Date: 2023-06-07

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 36

Registration Number: NCT00002826

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸
St. Francis Medical Center, Trenton, New Jersey, United States

and more 6 locations

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: paclitaxel
Drug: topotecan hydrochloride

First Posted Date: 2004-05-11

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00002587

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-05-05

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 470

Registration Number: NCT00002568

Locations: 🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 52 locations

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-03

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 17

Registration Number: NCT00005021

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: paclitaxel
Drug: vinorelbine tartrate

First Posted Date: 2004-05-03

Last Posted Date: 2017-07-13

Lead Sponsor: James Ahlgren

Registration Number: NCT00003622

Locations: 🇺🇸
George Washington University Hospital, Washington, D.C., District of Columbia, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary
Lung Cancer

First Posted Date: 2004-05-03

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT00003943

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-05-03

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 280

Registration Number: NCT00003972

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy